Perspective Therapeutics
CATX
43 hedge funds and large institutions have $9.99M invested in Perspective Therapeutics in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 8 closing their positions.
0.11% less ownership
Funds ownership: 1.23% → 1.12% (-0.11%)
10% less funds holding
Funds holding: 48 → 43 (-5)
28% less capital invested
Capital invested by funds: $13.9M → $9.99M (-$3.87M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$33K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$28.5K |
| 3 |
VF
Virtu Financial
New York
|
+$10.3K |
| 4 |
BA
Bard Associates
Chicago,
Illinois
|
+$7.36K |
| 5 |
TCWM
Total Clarity Wealth Management
St. Charles,
Illinois
|
+$2.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$945K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$68.8K |
| 3 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
-$38K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$28K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$27.6K |
CATX Hedge Fund Activity: Q3 2021 in Review
43 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2021, worth a combined $9.99M — down 28% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CATX and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $33K. The largest seller was Renaissance Technologies, cutting an estimated $945K.
- 43 institutional investors held Perspective Therapeutics (CATX) as of Q3 2021, down from 48 in Q2 2021.
- Funds reported $9.99M of Perspective Therapeutics stock for Q3 2021, down 28% quarter-over-quarter.
- 3 funds opened new Perspective Therapeutics positions in Q3 2021 and 8 closed out, a net change of -5 holders.
- The largest Perspective Therapeutics buyer in Q3 2021 was Marshall Wace, an estimated $33K added.
- The largest Perspective Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $945K sold.
Based on aggregated 13F filings for Q3 2021.